Skip to main content

REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products

Yokohama Japan, 23 May 2023: REPROCELL will now offer CDMO services to manufacture Advanced Therapies Medicinal Products (ATMPs) generated from mesenchymal stem cells (MSC) through a partnership with Histocell.

REPROCELL’s subcontracting partner, Histocell, has established an authorized GMP ATMP manufacturing facility in Bilbao, Spain. Histocell has been providing GMP manufacturing services since 2008 and is highly experienced in manufacturing clinical MSC products including cell-free MSC-derived secretome and exosome cell therapies.

REPROCELL will market this new service globally by combining the skillset of its experienced commercial and project management team. The company’s experience in managing MSC-based phase II clinical trials in Japan will add great value for clients employing REPROCELL’s MSC manufacturing offering.

“REPROCELL’s commercial expertise will enhance the reach of Histocell’s rich/broad GMP ATMP production. The service will be a great addition to REPROCELL’s clinical stem cell offering.” said Chikafumi Yokoyama Ph.D., CEO of REPROCELL Inc.

“Histocell reinforces our production and marketing capacity for GMP manufacturing of ATMPs. We are delighted to have REPROCELL as a strategic partner in the stem cell field.” said Julio Font Ph.D., CEO of Histocell, S.L.

About Histocell, S.L.
Histocell (headquartered at the Bizkaia Science and Technology Park, Bilbao, Spain), is a CDMO and a clinical-stage biopharmaceutical company, specializing in developing cell therapy products and novel medical devices for regenerative medicine.

Histocell also has its own pipelines including medical devices to enhance wound-healing processes (Reoxcare®, Vexoderm®), dermatologic tissue regeneration (Histoessence®, Wharton Gel Complex®, Neofibrin®), and cell therapy programs based on MSC for bone regeneration and an HC016-based cellular product (proprietary technology) for acute spinal cord injury and lung disease. On the top off the proven expertise as CDMO, Histocell has conducted several clinical trials with their MSC based GMP product HC016.

Learn more at

Subscribe to receive updates from REPROCELL